What did @invitewellnessllc actually say?
The creator, responding to a viewer question, said they would not recommend adding enclomiphene to a TRT protocol under any circumstances. Their argument rested on two points: first, that enclomiphene's "mechanism of action" makes it a poor fit alongside exogenous testosterone, and second, that HCG is the better tool if your goals are preserving testicular volume or fertility. They applied this position broadly, saying it holds whether TRT is done well or poorly.
The advice is short, confident, and delivered without much elaboration on the actual pharmacology. That brevity is worth noting, because the mechanism argument they gestured at is more complicated than a 45-second clip can handle. The fertility point, though, is reasonably grounded in how most TRT clinicians think about these options.
Does the science back this up?
Mostly, yes, but the reasoning deserves more precision than the creator offered. The core claim, that enclomiphene is poorly suited as an add-on to TRT, is supported by how the drug works. Whether HCG is categorically "better" depends on your specific clinical goal.
Enclomiphene is a selective estrogen receptor modulator, specifically the trans-isomer of clomiphene citrate. It works by blocking estrogen receptors in the hypothalamus, which tricks the brain into thinking estrogen is low and ramps up LH and FSH secretion. The entire mechanism depends on an intact hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone suppresses that axis. If the HPG axis is suppressed by TRT, there is no meaningful LH/FSH signal for enclomiphene to amplify, so the drug loses most of its clinical rationale. Kim et al. (2013, Fertility and Sterility) demonstrated enclomiphene's efficacy specifically in men with secondary hypogonadism who were not on exogenous testosterone. That context matters enormously.
HCG works differently. It mimics LH directly at the testicular level, stimulating Leydig cells to produce testosterone and supporting spermatogenesis downstream. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) showed HCG maintained intratesticular testosterone during exogenous testosterone administration. That is a legitimate, well-studied use case for combination TRT protocols.
What did they get wrong (or right)?
The fertility and testicular volume point is right. The mechanism framing is partially right but undersells what actually makes enclomiphene a mismatch here. The creator said enclomiphene's "mechanism of action is not a good choice" but never explained why, which leaves viewers without the actual insight.
What is missing: enclomiphene is not a bad drug. It has legitimate standalone applications for men with secondary hypogonadism who want to preserve fertility, as reviewed by Wiehle et al. (2014, Andrologia). Some clinicians use it as an alternative to TRT in younger men specifically because it does not suppress the HPG axis. The creator's framing, that enclomiphene is generally a poor choice, risks being read as a broader condemnation of the drug itself. That is an overreach. The accurate version is that enclomiphene and TRT work through mechanisms that conflict with each other, so combining them makes little pharmacological sense.
On the HCG point, they got the clinical logic right. HCG is the standard adjunct for men on TRT who want to maintain intratesticular testosterone, preserve testicular size, or keep fertility options open.
What should you actually know?
Enclomiphene is not a supplement or a hormone booster in the casual sense. It is a prescription-only SERM with a specific and narrow clinical application. Adding it to TRT is pharmacologically redundant at best, and potentially confusing at the HPG axis level. That is the honest version of what this creator was reaching for.
If you are on TRT and concerned about fertility or testicular atrophy, HCG is the established option with the most clinical support. Men who want to avoid suppressing their HPG axis entirely may be candidates for enclomiphene monotherapy, but that is a separate conversation that should happen with a licensed provider who can order baseline labs, including LH, FSH, and total testosterone.
- Enclomiphene works upstream, at the hypothalamus. TRT shuts down that upstream signal. The two work against each other.
- HCG works downstream, directly at the testes, which is why it can co-exist with TRT.
- Enclomiphene monotherapy is a legitimate, studied option for secondary hypogonadism, just not as a TRT add-on.
- No dose recommendations are appropriate here. Consult a licensed clinical provider for individualized evaluation.